DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Akums Drugs and Pharmaceuticals Limited — Press Release

NSE 2 hrs ago·8 Aug 2026, 11:31 am

Company NSE

Akums Drugs and Pharmaceuticals Limited has announced a press release, which was submitted to the stock exchange on August 08, 2026. The company has not disclosed the specific content of the communication at this time. This is a routine disclosure by the firm to inform the market about a significant update.

For investors, this development is notable as it signals that the company is preparing to share new information. While the exact nature of the news is currently unknown, such announcements often relate to regulatory approvals, financial results, or strategic corporate actions. Investors should wait for the full text of the release to understand the implications for the company's future.

What to watch next is the official release from Akums. The stock market will react based on the details provided in the press release. Investors should monitor the company's filings for clarity on the matter and assess how the market interprets the news before making any decisions.